The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma
Open accessAbstract
mAb OV569 was made by immunizing mice with ovarian carcinoma cells. It binds to cells from ovarian carcinomas and, to a lesser extent, to cells from certain other carcinomas whereas the binding to normal tissues is low to nondetectable. It also binds to soluble molecule(s) in culture supernatants from antigen-positive carcinomas. OV569 recognizes a protein(s) of 42–45 kDa with the same N-terminal amino acid sequence as the membrane-bound portion of mesothelin and megakaryocyte potentiating factor (MPF). Binding assays with fusion proteins comprising either the N-terminal part of mesothelin/MPF (D1Ig), reported to be easily cleaved off, or a noncleavable, membrane-associated part (D2Ig) showed that OV569 only binds to D2hIg. A new member of the mesothelin/MPF family was discovered, which has an 82-bp insert in the membrane-associated part, leading to a frameshift of 212 bp, and whose predicted molecular structure indicates that it is soluble. To test patient sera for soluble tumor antigen, antigen was isolated from cell-free tumor culture supernatants via immunoadsorption with OV569 and used to generate murine mAbs to an epitope different from the one to which OV569 binds, after which mAbs to two different epitopes were used to develop a “sandwich ELISA.” Using this assay, the level of circulating antigen was elevated significantly in 23 of 30 sera from patients with ovarian carcinoma, as compared with 0 of 68 sera from healthy controls, 0 of 3 sera from patients with nonneoplastic diseases, and 25 of 75 sera from patients with other tumors. Soluble molecules of the mesothelin/MPF family may provide useful new marker(s) for diagnosis of ovarian carcinoma and/or monitoring its response to therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The CA 125 tumour-associated antigen: a review of the literature
Jacobs, I., & Bast, R. C. (1989) · Human Reproduction · doi:10.1093/oxfordjournals.humrep.a136832 · Cited by 955
Chang, K., & Pastan, I. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.1.136 · Cited by 745
Wisdom, G. B. (1993) · FEBS Letters · doi:10.1016/0014-5793(93)80333-p · Cited by 579
Quantitative analysis of melanoma-associated antigen p97 in normal and neoplastic tissues.
Brown, J. P., Woodbury, R. G., Hart, C. E., Hellström, I., & Hellström, K. E. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.1.539 · Cited by 247
Self-citationChowdhury, P. S., Viner, J. L., Beers, R., & Pastan, I. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.2.669 · Cited by 222
Monoclonal mouse antibodies raised against human lung carcinoma
Hellstrom, I., Horn, D., Linsley, P. S., Brown, J., Brankovan, V., & Hellström, K. E. (1987) · Lung Cancer · doi:10.1016/s0169-5002(87)80426-9 · Cited by 129
Self-citationMolecular Cloning and Expression of Megakaryocyte Potentiating Factor cDNA
Kojima, T., Oh‐eda, M., Hattori, K., Taniguchi, Y., Tamura, M., Ochi, N., & Yamaguchi, N. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.37.21984 · Cited by 123
BOTTOMLEY (1998) · European Journal of Cancer Care · doi:10.1046/j.1365-2354.1998.00064.x · Cited by 28
Cleavable CD40Ig fusion proteins and the binding to sgp39
Hollenbaugh, D. L., Douthwright, J., McDonald, V. L., & Aruffo, A. A. (1995) · Journal of Immunological Methods · doi:10.1016/0022-1759(95)00194-8 · Cited by 19
Cited by
Recent progress in tumor pH targeting nanotechnology
Lee, E. S., Gao, Z., & Bae, Y. H. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.05.003 · Cited by 866
Moore, R. G., Brown, A. K., Miller, M. C., Skates, S., Allard, W. J., Verch, T., Steinhoff, M., Messerlian, G., DiSilvestro, P., Granai, C. O., et al. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2007.10.017 · Cited by 695
Robinson, B. W., Musk, A. W., & Lake, R. A. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67025-0 · Cited by 664
Binding of Ovarian Cancer Antigen CA125/MUC16 to Mesothelin Mediates Cell Adhesion
Rump, A., Morikawa, Y., Tanaka, M., Minami, S., Umesaki, N., Takeuchi, M., & Miyajima, A. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m312372200 · Cited by 572
Origin of myofibroblasts in the fibrotic liver in mice
Iwaisako, K., Jiang, C., Zhang, M., Cong, M., Moore-Morris, T. J., Park, T. J., Liu, X., Xu, J., Wang, P., Paik, Y.-H., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1400062111 · Cited by 535
Mesothelin-family proteins and diagnosis of mesothelioma
Robinson, B. W., Creaney, J., Lake, R., Nowak, A., Musk, A. W., de Klerk, N., Winzell, P., Hellstrom, K. E., & Hellstrom, I. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14794-0 · Cited by 534
New tumor markers: CA125 and beyond
BAST, R. C., BADGWELL, D., LU, Z., MARQUEZ, R., ROSEN, D., LIU, J., BAGGERLY, K. A., ATKINSON, E. N., SKATES, S., ZHANG, Z., et al. (2005) · International Journal of Gynecological Cancer · doi:10.1111/j.1525-1438.2005.00441.x · Cited by 504
Hassan, R., Bera, T., & Pastan, I. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0801 · Cited by 441
Lu, K. H., Patterson, A. P., Wang, L., Marquez, R. T., Atkinson, E. N., Baggerly, K. A., Ramoth, L. R., Rosen, D. G., Liu, J., Hellstrom, I., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0409 · Cited by 440
Lee, E. S., Gao, Z., Kim, D., Park, K., Kwon, I. C., & Bae, Y. H. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.04.024 · Cited by 400
Potential markers that complement expression of CA125 in epithelial ovarian cancer
Rosen, D. G., Wang, L., Atkinson, J. N., Yu, Y., Lu, K. H., Diamandis, E. P., Hellstrom, I., Mok, S. C., Liu, J., & Bast, R. C. (2005) · Gynecologic Oncology · doi:10.1016/j.ygyno.2005.06.040 · Cited by 385
Chimeric antigen receptor T cells: a novel therapy for solid tumors
Yu, S., Li, A., Liu, Q., Li, T., Yuan, X., Han, X., & Wu, K. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0444-9 · Cited by 306
Hassan, R., Remaley, A. T., Sampson, M. L., Zhang, J., Cox, D. D., Pingpank, J., Alexander, R., Willingham, M., Pastan, I., & Onda, M. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1477 · Cited by 296
Early Detection of Ovarian Cancer
Badgwell, D., & Bast, R. C. (2007) · Disease Markers · doi:10.1155/2007/309382 · Cited by 294
Kozak, K. R., Amneus, M. W., Pusey, S. M., Su, F., Luong, M. N., Luong, S. A., Reddy, S. T., & Farias-Eisner, R. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2033602100 · Cited by 276
Differential Gene Expression in Ovarian Carcinoma
Hibbs, K., Skubitz, K. M., Pambuccian, S. E., Casey, R. C., Burleson, K. M., Oegema, T. R., Thiele, J. J., Grindle, S. M., Bliss, R. L., & Skubitz, A. P. N. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63306-8 · Cited by 256
Discovery of Mesothelin and Exploiting It as a Target for Immunotherapy
Pastan, I., & Hassan, R. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0337 · Cited by 252
Scholler, N., & Urban, N. (2007) · Biomarkers in Medicine · doi:10.2217/17520363.1.4.513 · Cited by 220
Self-citationStructures of Cancer Antigen Mesothelin and Its Complexes with Therapeutic Antibodies
Zhan, J., Lin, D., Watson, N., Esser, L., Tang, W. K., Zhang, A., Liu, X., Hassan, R., Gleinich, A., Shajahan, A., et al. (2023) · Cancer Research Communications · doi:10.1158/2767-9764.crc-22-0306 · Cited by 28
Metadata
- Authors
- Scholler, N., Fu, N., Yang, Y., Ye, Z., Goodman, G. E., Hellström, K. E., & Hellström, I.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1999-09-28
- Volume
- 96
- Issue
- 20
- Pages
- 11531-11536
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W1985613060
- Cited by
- 344
- References
- 9
- FWCI
- 1.55
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.